
CRISPR Therapeutics AG (NASDAQ:CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day.
CRISPR Therapeutics stock plunged Tuesday during its Innovation Day after the company signaled that it was shifting its focus from its multiple myeloma candidate CTX120, to the newly developed CTX121.